Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Tide turn, successful injunction to stop frivolous legal claims, write off of credit card debt for this FY not as large as the accounts forecast, trading update showing the app is delivering increased engagement and revenue, a few more of the board buy in, staff reduction and offshoring beats budget again. CEO doesn't seem the type to report rubbish so at least updates should hopefully be able to be taken at face value. In my top drawer, but still adding a few on the drops.
I am a little more comfortable with the NAV as they have been probably supported in the context of a possible Fca review so audit and board would be on notice. However actual accounts may have to flag up post balance date events, so may not read as solid as this update with Graphcore bound to get a mention.
I have a concern about going private but mainly about lack of freedom. There are some heavy hitters amongst the iis so I don't think they will allow themselves to be shafted and will make the call, not management. I've had a buy in at 2.15 for a while, eventually hit, but it could easily go lower.
Ignoring the multinationals, nope. In bed with aijinmoto and you can't get much bigger in top line food tech. Loose change to them but they will do all they can to make it work as they have bought the dream and have the scientists to see it through if commercially viable. .
Note to self: Pay more attention to those who have been watching this for years and don't hang around for the divi...... Did flog a few for a few quid up and will average down almost risk free, but live and learn and try to do better next time with a bigger pot.
We are all mushrooms here Wild, unless you have a particular steer from those Hedge Fund mates of yours to share.
Meatly is dog food which is the point I was making. That should be the first commercial product off the shelves. Sure for human stand alone food products bring in the food critics, but meatly and liberation labs won't be in that space for a while.
I don't any of the dogs attending meatly's launch are going to be turned down so we should be OK at least for that one. Same with the other food additive development such eggs to be used in mass production. Unless the food critics want to chow down on dog food.
My takeaways, no real surprises..
Another chunky tranche of impairments from credit cards going to be realised this year.
Headcount reduction well ahead of target, so cost savings should exceed original plan.
Revenue looks sound
App may be generating noise, buts that's all it generated to year end
Chairman staked 100% of his his salary buying in
CEO does have a chunky performance component but won't be crying poor if he misses out.
Solvency etc all good
160+ pages, anyone else?
It is a discussion board where everyone is entitled to an opinion, even if it is wishful thinking. Take all or part of it or reject it, I don't mind. I'd love your predictions to come true, just think it is probably not yet.
They will not want to go to Nasdac without crystalising the grant shares first They are are not contemplated for a carry over. For a reverse you need a failed Nasdac Co with some cash.so you take control not share it. Cash is needed as intangibles won't cut it for valuing the shares on merger for the 4USD min. The phase 2 cash probably wont be delivered in one chunk so at the moment they need more than I can see coming in to do it.
I don't care if the ceo buys shares the performance related package means he will have to deliver or miss out. Plenty of CEOs don't buy because they can't sell until they leave the job. Chair however would need to buy in to get the same upside. CEO delivers and the share price and div is restored. He buys in but fails to deliver it will end up sub 50.
I see a ramp up in the European ops to service expanded offerings to French and German telcos and now insurance clients from the Polish offices. These are profitable contracts in an area where Capita has a good name. Bulgaria service centre doesn't look like it has much traction in comparison.
I'm also not comfortable with the apparent conflict of interest, it would need to be declared at pretty much every board meeting. However I think the core portfolio is generating sufficient momentum and excellent press coverage that at the end of the day there will be enough of the pie to share around so we can all get a feed.
Nice find eirico, but will need to get the share price up unless you are happy with a 40:1 reduction to meet Nasdac minimum. I'm not. I'm not sure it would generate much interest with a couple of phase 1 trials under the belt. Let's bed down the £15+ million needed for the phase 2 and to keep the ship afloat and grow the pipeline for the next couple of years whilst that happens and then if success it will fly.